Premium
Ana o 1 and Ana o 2 cashew allergens share cross‐reactive CD 4 + T cell epitopes with other tree nuts
Author(s) -
Archila L. D.,
Chow IT.,
McGinty J. W.,
Renand A.,
Jeong D.,
Robinson D.,
Farrington M. L.,
Kwok W. W.
Publication year - 2016
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.12746
Subject(s) - epitope , t cell , cashew nut , cross reactivity , allergen , biology , immunology , antigen , allergy , cross reactions , immune system , food science
Summary Background Allergies to cashew are increasing in prevalence, with clinical symptoms ranging from oral pruritus to fatal anaphylactic reaction. Yet, cashew‐specific T cell epitopes and T cell cross‐reactivity amongst cashew and other tree nut allergens in humans remain uncharacterized. Objectives In this study, we characterized cashew‐specific T cell responses in cashew‐allergic subjects and examined cross‐reactivity of these cashew‐specific cells towards other tree nut allergens. Methods CD 154 up‐regulation assay was used to determine immunodominance hierarchy among cashew major allergens at the T cell level. The phenotype, magnitude and functionality of cashew‐specific T cells were determined by utilizing ex vivo staining with MHC class II tetramers. Dual tetramer staining and proliferation experiments were used to determine cross‐reactivity to other tree nuts. Results CD 4 + T cell responses were directed towards cashew allergens Ana o 1 and Ana o 2. Multiple Ana o 1 and Ana o 2 T cell epitopes were then identified. These epitopes elicited either T H 2 or T H 2/ T H 17 responses in allergic subjects, which were either cashew unique epitope or cross‐reactive epitopes. For clones that recognized the cross‐reactive epitope, T cell clones responded robustly to cashew, hazelnut and/or pistachio but not to walnut. Conclusions Phylogenetically diverse tree nut allergens can activate cashew‐reactive T cells and elicit a T H 2‐type response at an epitope‐specific level. Clinical relevance Lack of cross‐reactivity between walnut and cashew suggests that cashew peptide immunotherapy approach may not be most effective for walnut.